Notably, when combined with daratumumab (an anti-CD38 monoclonal antibody), iDuo-MM-CAR-NK cells achieved maximal ADCC activity and anti-tumor efficacy against multiple myeloma (MM) [113]. Here, CD38 is linked to plasma cell myeloma.